☆ 4.8 Editorial Material

Tailoring duration of DAPT with risk scores

LANCET (2017)

Get Full Text
Add to Collection

Journal

LANCET
Volume 389, Issue 10073, Pages 987-989

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)30591-3

Keywords

-

Categories

Medicine, General & Internal

Funding

  1. AstraZeneca
  2. Bayer
  3. Daiichi Sankyo
  4. Eli Lilly
  5. Medicines Company
  6. Abbott Vascular
  7. Amgen
  8. Chiesi
  9. Merck
  10. Pfizer
  11. PLx Pharma
  12. Sanofi
  13. CSL Behring
  14. Gilead
  15. GlaxoSmithKline
  16. Janssen Pharmaceuticals
  17. Novartis
  18. Osprey Medical

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.